Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling act...
Main Authors: | Mi Seong Kim, So Hui Kim, Sei Hoon Yang, Min Seuk Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0238155 |
Similar Items
-
CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
by: Jian He, et al.
Published: (2023-03-01) -
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
by: Hanna Björkelund, et al.
Published: (2011-01-01) -
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01) -
Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
by: Heng Sun, et al.
Published: (2018-06-01) -
M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
by: Fengqi Xiao, et al.
Published: (2020-11-01)